With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
The company also raised Rs 270 crore investment from Temasek in 2019
The partners also aim to expand their work to Latin America for the first time
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Avacc 3 has significant advantages over existing whooping cough vaccines
He will be leading the business, operations, P&L, and growth strategy for StanPlus
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Subscribe To Our Newsletter & Stay Updated
